These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30119271)

  • 1. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.
    Singh MK; Das BK; Choudhary S; Gupta D; Patil UK
    Biomed Pharmacother; 2018 Oct; 106():991-1002. PubMed ID: 30119271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
    Noureddin M; Rinella ME
    Clin Liver Dis; 2015 May; 19(2):361-79. PubMed ID: 25921668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives.
    Facciorusso A
    Curr Diabetes Rev; 2013 Sep; 9(5):382-6. PubMed ID: 23845075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
    Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
    Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma?
    Gao C; Yao SK
    Hepatobiliary Pancreat Dis Int; 2009 Oct; 8(5):465-73. PubMed ID: 19822488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
    Hsieh MH; Kao TY; Hsieh TH; Kao CC; Peng CY; Lai HC; Chuang PH; Kao JT
    PLoS One; 2020; 15(12):e0244293. PubMed ID: 33382703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
    Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
    Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus and endometrial carcinoma: Risk factors and etiological links.
    Wang Y; Zeng X; Tan J; Xu Y; Yi C
    Medicine (Baltimore); 2022 Aug; 101(34):e30299. PubMed ID: 36042597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
    Das BK; Choukimath SM; Gadad PC
    Life Sci; 2019 Aug; 230():10-18. PubMed ID: 31121175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
    Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
    Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes Mellitus and Risk of Hepatocellular Carcinoma.
    Li X; Wang X; Gao P
    Biomed Res Int; 2017; 2017():5202684. PubMed ID: 29379799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives.
    Vrachnis N; Iavazzo C; Iliodromiti Z; Sifakis S; Alexandrou A; Siristatidis C; Grigoriadis C; Botsis D; Creatsas G
    Arch Gynecol Obstet; 2016 Feb; 293(2):239-46. PubMed ID: 26338721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
    Li Q; Xu H; Sui C; Zhang H
    Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101781. PubMed ID: 34332136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus.
    Konishi I; Hiasa Y; Shigematsu S; Hirooka M; Furukawa S; Abe M; Matsuura B; Michitaka K; Horiike N; Onji M
    Liver Int; 2009 Sep; 29(8):1194-201. PubMed ID: 19422477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Herrigel DJ; Moss RA
    Postgrad Med; 2014 Oct; 126(6):106-18. PubMed ID: 25414939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study.
    Lin CM; Huang HL; Chu FY; Fan HC; Chen HA; Chu DM; Wu LW; Wang CC; Chen WL; Lin SH; Ho SY
    PLoS One; 2015; 10(5):e0125421. PubMed ID: 25978841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes mellitus and metformin in hepatocellular carcinoma.
    Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
    World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma.
    Hessheimer AJ; Forner A; Varela M; Bruix J
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1239-44. PubMed ID: 20505515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.